NO315355B1 - Anvendelse av gassformig NO for fremstilling av et medikament, produkt sominneholder gassformig NO og anvendelse derav med en andreforbindelse - Google Patents
Anvendelse av gassformig NO for fremstilling av et medikament, produkt sominneholder gassformig NO og anvendelse derav med en andreforbindelse Download PDFInfo
- Publication number
- NO315355B1 NO315355B1 NO19973768A NO973768A NO315355B1 NO 315355 B1 NO315355 B1 NO 315355B1 NO 19973768 A NO19973768 A NO 19973768A NO 973768 A NO973768 A NO 973768A NO 315355 B1 NO315355 B1 NO 315355B1
- Authority
- NO
- Norway
- Prior art keywords
- gaseous
- use according
- mammal
- inhaled
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 208000007536 Thrombosis Diseases 0.000 claims description 62
- 241000124008 Mammalia Species 0.000 claims description 41
- 230000002792 vascular Effects 0.000 claims description 41
- 206010051113 Arterial restenosis Diseases 0.000 claims description 33
- 206010020718 hyperplasia Diseases 0.000 claims description 26
- 210000004351 coronary vessel Anatomy 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 230000002265 prevention Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 19
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 238000002399 angioplasty Methods 0.000 claims description 9
- 229960004676 antithrombotic agent Drugs 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- KFMVHONQQFRNNH-UHFFFAOYSA-N 5-(2-propoxyphenyl)triazolo[4,5-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NN=NC2=N1 KFMVHONQQFRNNH-UHFFFAOYSA-N 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 5
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 4
- 229960002768 dipyridamole Drugs 0.000 claims description 4
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 4
- 230000003389 potentiating effect Effects 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 3
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 241000208125 Nicotiana Species 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 108010023197 Streptokinase Proteins 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 229960005202 streptokinase Drugs 0.000 claims description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 3
- 229960005001 ticlopidine Drugs 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 390
- 239000007789 gas Substances 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 239000003570 air Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 15
- 210000001367 artery Anatomy 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 210000004623 platelet-rich plasma Anatomy 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 8
- 229910002089 NOx Inorganic materials 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000034827 Neointima Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000002537 thrombolytic effect Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 206010038563 Reocclusion Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 5
- 210000001715 carotid artery Anatomy 0.000 description 5
- 208000002528 coronary thrombosis Diseases 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000000250 revascularization Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 229920006384 Airco Polymers 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010061951 Methemoglobin Proteins 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000013147 laser angioplasty Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000007491 morphometric analysis Methods 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002840 nitric oxide donor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940019331 other antithrombotic agent in atc Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- ZPGKBYMJBZKMAM-UHFFFAOYSA-I calcium;potassium;barium(2+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[K+].[Ca+2].[Ba+2] ZPGKBYMJBZKMAM-UHFFFAOYSA-I 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000021061 grooming behavior Effects 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010059557 kistrin Proteins 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 superoxide radicals Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/389,304 US6063407A (en) | 1995-02-16 | 1995-02-16 | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
PCT/US1996/001745 WO1996025184A1 (en) | 1995-02-16 | 1996-02-08 | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
Publications (3)
Publication Number | Publication Date |
---|---|
NO973768D0 NO973768D0 (no) | 1997-08-15 |
NO973768L NO973768L (no) | 1997-10-15 |
NO315355B1 true NO315355B1 (no) | 2003-08-25 |
Family
ID=23537703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19973768A NO315355B1 (no) | 1995-02-16 | 1997-08-15 | Anvendelse av gassformig NO for fremstilling av et medikament, produkt sominneholder gassformig NO og anvendelse derav med en andreforbindelse |
Country Status (19)
Country | Link |
---|---|
US (2) | US6063407A (ja) |
EP (1) | EP0810884B1 (ja) |
JP (1) | JP3956055B2 (ja) |
KR (1) | KR100426528B1 (ja) |
CN (1) | CN1327826C (ja) |
AR (1) | AR000960A1 (ja) |
AT (1) | ATE324866T1 (ja) |
AU (1) | AU690425B2 (ja) |
BR (1) | BR9607616A (ja) |
CZ (1) | CZ289677B6 (ja) |
DE (1) | DE69636096T2 (ja) |
DK (1) | DK0810884T3 (ja) |
ES (1) | ES2263159T3 (ja) |
FI (1) | FI119912B (ja) |
HU (1) | HUP9802093A3 (ja) |
NO (1) | NO315355B1 (ja) |
PT (1) | PT810884E (ja) |
WO (1) | WO1996025184A1 (ja) |
ZA (1) | ZA961183B (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
USRE37234E1 (en) | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
AU722480B2 (en) * | 1996-11-01 | 2000-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
CN1191832C (zh) * | 1997-08-27 | 2005-03-09 | 三菱制药株式会社 | 血管生成促进剂 |
US5994444A (en) * | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
US6656452B1 (en) | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
CA2350028C (en) * | 1998-11-06 | 2013-04-09 | University Of Rochester | A method to improve circulation to ischemic tissue |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US6612306B1 (en) | 1999-10-13 | 2003-09-02 | Healthetech, Inc. | Respiratory nitric oxide meter |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
EP1301500B1 (en) | 2000-06-22 | 2007-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6601580B1 (en) | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
IL153956A0 (en) | 2000-08-11 | 2003-07-31 | Whitlock David R | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
WO2002024208A1 (en) * | 2000-09-20 | 2002-03-28 | Aquamed Technologies, Inc. | Compositions comprising lignin and methods of making and using the same |
WO2002026112A2 (en) | 2000-09-29 | 2002-04-04 | Healthetech, Inc. | Indirect calorimetry system |
ATE316787T1 (de) * | 2000-10-26 | 2006-02-15 | Fournier Lab Ireland Ltd | Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7335181B2 (en) * | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
HUP0400371A3 (en) | 2001-06-21 | 2010-06-28 | Beth Israel Hospital | Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation |
US20070173460A1 (en) * | 2001-09-20 | 2007-07-26 | Oculus Innovative Sciences, Inc. | Compositions comprising lignin and methods of making and using the same |
US20030070674A1 (en) * | 2001-10-12 | 2003-04-17 | Bryan Perry | Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine |
GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
CA2473097A1 (en) * | 2002-01-11 | 2003-07-17 | David R. Whitlock | Compositions including ammonia oxidizing bacteria and methods of using same |
US7086397B2 (en) * | 2002-02-16 | 2006-08-08 | Graham Lindley Spruiell | Patient usable emergency medical kit |
EP1515753A4 (en) * | 2002-06-21 | 2009-07-15 | Univ Pittsburgh | PHARMACEUTICAL USE OF NITROGEN MONOXIDE, HEME OXYGENASE-1 AND HEME DEGRADATION PRODUCTS |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
US9138707B2 (en) | 2002-12-10 | 2015-09-22 | Sy Kimball | Portable, nitric oxide generator |
CA2536827C (en) * | 2003-07-09 | 2014-09-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
JP2007508247A (ja) * | 2003-09-26 | 2007-04-05 | ホイットロック,デービッド,アール. | アンモニア酸化細菌の使用方法 |
CN100475275C (zh) * | 2004-01-05 | 2009-04-08 | 董永华 | 肿瘤血管栓塞剂及其储存和释放装置 |
US20050255178A1 (en) * | 2004-02-04 | 2005-11-17 | Bloch Kenneth D | Enhancing the effectiveness of an inhaled therapeutic gas |
AU2005244078A1 (en) * | 2004-05-11 | 2005-11-24 | Pulmonox Technologies Corporation | Intermittent dosing of nitric oxide gas |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
WO2006125123A2 (en) * | 2005-05-19 | 2006-11-23 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
WO2007057763A2 (en) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
WO2008063868A2 (en) | 2006-11-07 | 2008-05-29 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
US9649467B2 (en) | 2008-01-31 | 2017-05-16 | Syk Technologies, Llc | Nitric oxide reactor and distributor apparatus and method |
US8434475B2 (en) * | 2008-01-31 | 2013-05-07 | Genosys, Inc. | Nitric oxide reactor and distributor apparatus and method |
US8720436B2 (en) * | 2008-01-31 | 2014-05-13 | Genosys, Inc. | Nitric oxide gel apparatus and method |
US8501090B2 (en) * | 2008-03-24 | 2013-08-06 | Christian S. Minton | Anti-microbial gas apparatus and method |
WO2010011928A1 (en) * | 2008-07-24 | 2010-01-28 | Geno Llc | Methods for diagnosing and treating a heart condition in a patient |
CA3130908A1 (en) | 2009-06-30 | 2010-12-30 | Mallinckrodt Hospital Products IP Limited | Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
US8685467B2 (en) | 2010-08-03 | 2014-04-01 | J. W. Randolph Miller | Nitric oxide generation, dilution, and topical application apparatus and method |
US20120107423A1 (en) | 2010-11-01 | 2012-05-03 | Ino Therapeutics Llc | Methods of Using Inhaled Nitric Oxide Gas for Treatment of Acute Respiratory Distress Syndrome |
EP2776047A4 (en) | 2011-11-07 | 2015-07-22 | Gen Hospital Corp | TREATMENT OF RED GLOBLES |
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
WO2015048747A1 (en) * | 2013-09-30 | 2015-04-02 | Northwestern University | Targeted therapy for the prevention of restenosis in the cardiovascular system |
AU2015204616B2 (en) | 2014-01-10 | 2020-04-02 | Mallinckrodt Hospital Products IP Limited | Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
CA3207619A1 (en) | 2014-04-15 | 2015-10-22 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
EP3247332A1 (en) * | 2015-01-20 | 2017-11-29 | Incarda Therapeutics, Inc. | Unit aerosol doses for anticoagulation |
EP3407900B1 (en) | 2016-01-27 | 2024-01-10 | SYK Technologies, LLC | Nitric oxide topical application apparatus and methods |
CA3237305A1 (en) * | 2021-11-03 | 2023-05-11 | Baxter International Inc. | Nitric oxide donors for use in surgical recovery |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3785377A (en) * | 1970-11-12 | 1974-01-15 | S Jorgensen | Plant, preferably for anaesthesia |
US4010897A (en) * | 1976-03-31 | 1977-03-08 | Charles F. Kettering Foundation | Method and apparatus for home production and application of nitrogen fertilizer |
IL57239A (en) * | 1979-05-08 | 1982-04-30 | Alamaro Moshe | Production of nitric oxides |
US4297123A (en) * | 1980-02-07 | 1981-10-27 | Wyse Harold G | Method and apparatus for producing a nitrate fertilizer |
US4336798A (en) * | 1980-10-06 | 1982-06-29 | Anthony V. Beran | Medical corrugated respiratory tube |
SE438261B (sv) * | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
US4534343A (en) * | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
US4592348A (en) * | 1984-12-17 | 1986-06-03 | Waters Iv William C | Aerosol inhaler |
CN87107609A (zh) * | 1987-11-12 | 1988-09-14 | 赵树杰 | 脑血栓治疗仪 |
US4852561A (en) * | 1988-07-27 | 1989-08-01 | Sperry C R | Inhalation device |
US4877589A (en) * | 1988-09-19 | 1989-10-31 | Hare Louis R O | Nitrogen fixation by electric arc and catalyst |
US4915915A (en) * | 1988-10-11 | 1990-04-10 | Treharne Richard W | Water-powdered piezoelectric unit for producing nitrogen fertilizer |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5396882A (en) * | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
US5570683A (en) * | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5536241A (en) * | 1990-12-05 | 1996-07-16 | The General Hospital Corporation | Methods and devices for relaxing smooth muscle contractions |
DE69133575T2 (de) * | 1990-12-05 | 2008-04-17 | The General Hospital Corp., Boston | Verwendung von NO zur Behandlung der persistenten pulmonaren Hypertonie des Neugeborenen |
IL101406A (en) * | 1991-03-29 | 1998-02-08 | Brigham & Womens Hospital | Pharmaceutical compositions containing s-nitrosothiol derivatives |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5185376A (en) * | 1991-09-24 | 1993-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof |
WO1993012068A1 (en) * | 1991-12-11 | 1993-06-24 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
US5650447A (en) * | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
CN1083707A (zh) * | 1992-09-05 | 1994-03-16 | 沈阳康达制药厂 | 一种脑血栓片的生产工艺 |
FR2695831B1 (fr) * | 1992-09-24 | 1994-11-10 | Air Liquide | Installation et procédé de fourniture d'un mélange gazeux aux voies respiratoires d'un utilisateur. |
WO1994016729A1 (en) * | 1993-01-28 | 1994-08-04 | Neorx Corporation | Targeted nitric oxide pathway or nitric oxide synthase modulation |
US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
US5428070A (en) * | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
ATE191560T1 (de) * | 1993-07-06 | 2000-04-15 | Aerocrine Ab | System zur feststellung von no-pegeln in ausgeatmeter luft und diagnostische verfahren für zu abnormalen no-pegeln in beziehung stehenden abweichungen |
DE4327731C1 (de) * | 1993-08-18 | 1994-11-10 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
DE4327732C1 (de) * | 1993-08-18 | 1994-09-01 | Messer Griesheim Gmbh | NO-haltiges Gasgemisch zur Behandlung pulmonaler Erkrankungen |
GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US5660873A (en) * | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5521191A (en) * | 1994-10-17 | 1996-05-28 | Washington University | Method for treatment of arterial stenosis |
EP0799051B1 (en) * | 1994-12-12 | 2005-07-27 | Omeros Corporation | Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
US5823180A (en) * | 1995-04-03 | 1998-10-20 | The General Hospital Corporation | Methods for treating pulmonary vasoconstriction and asthma |
ES2267141T3 (es) * | 1996-04-05 | 2007-03-01 | The General Hospital Corporation | Tratamiento de una hemoglobinopatia. |
-
1995
- 1995-02-16 US US08/389,304 patent/US6063407A/en not_active Expired - Fee Related
-
1996
- 1996-02-08 AT AT96903806T patent/ATE324866T1/de active
- 1996-02-08 WO PCT/US1996/001745 patent/WO1996025184A1/en active IP Right Grant
- 1996-02-08 BR BR9607616A patent/BR9607616A/pt not_active Application Discontinuation
- 1996-02-08 CN CNB961919299A patent/CN1327826C/zh not_active Expired - Fee Related
- 1996-02-08 PT PT96903806T patent/PT810884E/pt unknown
- 1996-02-08 DK DK96903806T patent/DK0810884T3/da active
- 1996-02-08 CZ CZ19972598A patent/CZ289677B6/cs not_active IP Right Cessation
- 1996-02-08 ES ES96903806T patent/ES2263159T3/es not_active Expired - Lifetime
- 1996-02-08 EP EP96903806A patent/EP0810884B1/en not_active Expired - Lifetime
- 1996-02-08 KR KR1019970705582A patent/KR100426528B1/ko not_active IP Right Cessation
- 1996-02-08 JP JP52502296A patent/JP3956055B2/ja not_active Expired - Fee Related
- 1996-02-08 AU AU47775/96A patent/AU690425B2/en not_active Ceased
- 1996-02-08 DE DE69636096T patent/DE69636096T2/de not_active Expired - Lifetime
- 1996-02-08 HU HU9802093A patent/HUP9802093A3/hu unknown
- 1996-02-14 ZA ZA961183A patent/ZA961183B/xx unknown
- 1996-02-15 AR ARP960101393A patent/AR000960A1/es unknown
-
1997
- 1997-01-17 US US08/785,529 patent/US5904938A/en not_active Expired - Lifetime
- 1997-08-15 FI FI973357A patent/FI119912B/fi not_active IP Right Cessation
- 1997-08-15 NO NO19973768A patent/NO315355B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA961183B (en) | 1996-12-17 |
AU690425B2 (en) | 1998-04-23 |
CZ259897A3 (cs) | 1998-05-13 |
ES2263159T3 (es) | 2006-12-01 |
CN1327826C (zh) | 2007-07-25 |
DE69636096D1 (de) | 2006-06-08 |
EP0810884A1 (en) | 1997-12-10 |
EP0810884B1 (en) | 2006-05-03 |
HUP9802093A3 (en) | 2001-02-28 |
KR19980702187A (ko) | 1998-07-15 |
CN1174513A (zh) | 1998-02-25 |
FI973357A (fi) | 1997-08-15 |
AU4777596A (en) | 1996-09-04 |
DK0810884T3 (da) | 2006-08-28 |
FI973357A0 (fi) | 1997-08-15 |
DE69636096T2 (de) | 2006-12-07 |
EP0810884A4 (en) | 2002-05-08 |
JPH11500125A (ja) | 1999-01-06 |
KR100426528B1 (ko) | 2004-06-30 |
CZ289677B6 (cs) | 2002-03-13 |
US6063407A (en) | 2000-05-16 |
ATE324866T1 (de) | 2006-06-15 |
NO973768L (no) | 1997-10-15 |
HUP9802093A2 (hu) | 2000-06-28 |
BR9607616A (pt) | 1998-06-09 |
PT810884E (pt) | 2006-08-31 |
FI119912B (fi) | 2009-05-15 |
WO1996025184A1 (en) | 1996-08-22 |
AR000960A1 (es) | 1997-08-27 |
NO973768D0 (no) | 1997-08-15 |
MX9706257A (es) | 1997-11-29 |
JP3956055B2 (ja) | 2007-08-08 |
US5904938A (en) | 1999-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO315355B1 (no) | Anvendelse av gassformig NO for fremstilling av et medikament, produkt sominneholder gassformig NO og anvendelse derav med en andreforbindelse | |
Fang et al. | The role of NO in COVID-19 and potential therapeutic strategies | |
CA2383174C (en) | Method of treating cardio pulmonary diseases with no group compounds | |
Steudel et al. | Inhaled nitric oxide: basic biology and clinical applications | |
ES2554108T3 (es) | Métodos de tratamiento de la enterocolitis necrosante | |
US6656452B1 (en) | Use of inhaled NO as anti-inflammatory agent | |
US20050255178A1 (en) | Enhancing the effectiveness of an inhaled therapeutic gas | |
EP0914103A1 (en) | Treatment of a hemoglobinopathy | |
Combes et al. | Effect of 48 hours of nitric oxide inhalation on pulmonary vasoreactivity in rats | |
Kouretas et al. | Heparin preserves nitric oxide activity in coronary endothelium during ischemia-reperfusion injury | |
Lindberg et al. | Inhaled nitric oxide reveals and attenuates endothelial dysfunction after lung transplantation | |
CA2213188C (en) | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide | |
Glavind‐Kristensen et al. | Pulmonary endothelial dysfunction after cardiopulmonary bypass in neonatal pigs | |
MXPA97006257A (en) | Treatment of vascular thrombosis and restenosis with inhal nitric oxide | |
Ichinose et al. | Inhaled nitric oxide—current practice and future potential uses and development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |